In vivo Testing of Nanotherapeutics for Osteosarcoma Treatment: Translational Challenges and Solutions

Area of Science:

• Oncology
• Nanotechnology
• Pharmacology

Background:

• Osteosarcoma (OS) is an aggressive bone cancer common in children and adolescents, often metastasizing to the lungs.
• Current standard treatments (MAP regimen) have remained unchanged for over 40 years, facing issues like drug resistance, recurrence, and severe side effects.
• Multifunctional nanocarriers offer targeted drug delivery to enhance efficacy and reduce toxicity in OS treatment.

Purpose of the Study:

• To provide a systematic analysis of in vivo studies using nanosystems for osteosarcoma management.
• To review advancements in nanomedicine, drug delivery, and cutting-edge therapies (chemo-, immuno-, gene) for OS.
• To identify the potential and challenges of nanotherapeutics in clinical applications for OS.

Main Methods:

• Systematic review of in vivo studies published in the last decade.
• Analysis of research employing multifunctional nanosystems and advanced drug delivery strategies.
• Evaluation of chemo-, immuno-, and gene therapy approaches for OS using nanocarriers.

Main Results:

• Nanosystems demonstrated significant antitumoral effects in preclinical osteosarcoma models.
• Targeted drug delivery via nanocarriers showed potential for improved accumulation and reduced systemic toxicity.
• Despite promising preclinical results, significant translational challenges hinder clinical application.

Conclusions:

• Nanomedicine holds potential for improving osteosarcoma treatment outcomes.
• Overcoming translational bottlenecks and understanding OS tumor heterogeneity are crucial for clinical success.
• Future research should focus on combination regimens and personalized therapies, supported by long-term clinical observations.